(Q37552019)

English

Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy

scientific article published on August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy (English)

1 reference

Europe PubMed Central

21 August 2017

1 reference

based on heuristic

inferred from title

author name string

M J Leandro

1

1 reference

Europe PubMed Central

21 August 2017

I de la Torre

2

1 reference

Europe PubMed Central

21 August 2017

publication date

1 August 2009

1 reference

Europe PubMed Central

21 August 2017

Clinical and Experimental Immunology

1 reference

Europe PubMed Central

21 August 2017

157

1 reference

Europe PubMed Central

21 August 2017

2

1 reference

Europe PubMed Central

21 August 2017

191-197

1 reference

Europe PubMed Central

21 August 2017

Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03978.X

21 January 2018

The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03978.X

21 January 2018

Life threatening steroid-resistant autoimmune anemia successfully treated with rituximab: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

The BLyS family: toward a molecular understanding of B cell homeostasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Plasma cell differentiation and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Epidemiology and pathophysiology of immune thrombocytopenic purpura

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Thyrotropin receptor autoantibodies (TSHRAbs): epitopes, origins and clinical significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

The role of antibodies and B cells in the pathogenesis of lupus nephritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Rituximab treatment results in impaired secondary humoral immune responsiveness.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Pemphigus: autoimmune diseases of keratinocyte's adhesion molecules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

The sequential role of lymphotoxin and B cells in the development of splenic follicles.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Production of cytokines by human B cells in health and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

5 November 2018

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

3 December 2018

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730844

3 December 2018

Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reciprocal regulation of polarized cytokine production by effector B and T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical findings leading to the diagnosis of X-linked agammaglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituxan in the treatment of cold agglutinin disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

To 'B' regulated: B cells as members of the regulatory workforce

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab for the treatment of type II mixed cryoglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2249.2009.03978.X

1 reference

Europe PubMed Central

21 August 2017

0 references

1 reference

Europe PubMed Central

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37552019&oldid=1710877207"